Merck Announces Collaboration With Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
Mersana to receive $30 million upfront payment, up to $800 million in development, regulatory and commercial milestones, as well as royalties on net sales
27-Dec-2022 -
Merck announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates (ADCs) leveraging Mersana’s proprietary Immunosynthen STING-agonist ADC platform, directed against up to two targets. ...
antibody drug conjugates (ADCs)
immunotherapies
Merck
+1